Litigation Details for SHIONOGI INC. v. NOSTRUM LABORATORIES, INC. (D.N.J. 2012)

SHIONOGI INC. v. NOSTRUM LABORATORIES, INC. (D.N.J. 2012)

Docket		Date Filed	2012-07-13
Court	District Court, D. New Jersey	Date Terminated	2013-05-03
Cause	35:271 Patent Infringement	Assigned To	Robert B. Kugler
Jury Demand	None	Referred To	Joel Schneider
Patents	6,010,718; 6,099,859; 6,866,866
Link to Docket	External link to docket

Details for SHIONOGI INC. v. NOSTRUM LABORATORIES, INC. (D.N.J. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-07-13				External link to document

Litigation summary and analysis for: SHIONOGI INC. v. NOSTRUM LABORATORIES, INC. (D.N.J. 2012)

Last updated: June 29, 2026

Shionogi v. Nostrum 1:12-cv-04402: Litigation Summary, Patent Claims, and Exclusivity/Generic-Entry Risk

Shionogi Inc. v. Nostrum Laboratories Inc. (D.N.J.) is a Hatch-Waxman patent dispute tied to SHIONOGI’s NDA-era product and related patent estate, with the case docket reflecting a typical Paragraph IV framework: branded patent infringement allegations, defensive noninfringement/invalidity positions by the generic filer, and litigation outcomes that determine whether Nostrum (and its commercial plans) can launch before patent expiry and associated exclusivity windows.

What the docket number indicates: the matter is a federal Hatch-Waxman (28 U.S.C. § 355(b) format) lawsuit filed in 2012, consistent with Paragraph IV litigation brought after FDA acceptance of an ANDA referencing a Shionogi-listed drug (and Orange Book patent listings).

What this summary focuses on: litigation posture, procedural milestones, and the business implications for generic entry timing and settlement leverage.

---

What is the litigation posture in Shionogi Inc. v. Nostrum Laboratories 1:12-cv-04402?

Core structure of the case (Hatch-Waxman pattern):

• Shionogi (plaintiff) asserts one or more Orange Book patents listed for the referenced brand.
• Nostrum (defendant) challenges the asserted patents via defenses typical in Paragraph IV litigation:
  • noninfringement,
  • invalidity (anticipation, obviousness, lack of enablement, improper statutory subject matter, or indefiniteness depending on claim set),
  • and often non-infringement against the ANDA product/process as described in the ANDA and infringement contentions.
• The court’s schedule and any stay/expedition mechanisms usually tie to FDA approval timelines and statutory timing for ANDA decisions.

How to interpret docket-driven risk:

• If the case results in an early dismissal or narrowing of asserted claims, generic launch risk rises.
• If the court sustains infringement or denies invalidity, generic launch risk falls and may require design-around or licensing.

---

Which patents were asserted in SHIONOGI Inc. v. NOSTRUM Laboratories, Inc. (1:12-cv-04402)?

No specific patent numbers, claims, or asserted listings are included in the request content. Under the operating constraint, this response cannot supply patent numbers or identify claim scope without reliable, docket-grounded details.

Practical impact of knowing the asserted patents:

• Patent identity determines:
  • expiration dates,
  • whether any “method of use” or “formulation” barriers apply,
  • whether a partial injunction is possible,
  • and whether a design-around can avoid infringement.

---

What procedural milestones matter in Shionogi v. Nostrum (1:12-cv-04402)?

For business planning, the milestones that usually govern entry are:

1) Case filing and initial Rule 16/Markman handling

• Filing date anchors the litigation timeline.
• Early scheduling controls claim construction and the pace of dispositive motions.

2) Preliminary injunction or temporary relief

• Rarely, plaintiffs seek a temporary injunction tied to likelihood of infringement and irreparable harm.
• In Hatch-Waxman, most timing questions resolve through final judgments and statutory stay mechanics rather than TRO practice.

3) Claim construction (Markman)

• Markman outcomes directly alter infringement and invalidity paths.
• Narrow constructions favor noninfringement; broad constructions can pressure the generic.

4) Dispositive motions

• Common: summary judgment on noninfringement, invalidity, or both.
• Outcome determines settlement value and generic launch probability.

5) Trial (if it proceeds) and final judgment

• If the case reaches trial, claim construction plus expert testimony drive infringement findings.
• Final judgment triggers:
  • injunction scope,
  • appeal leverage,
  • and FDA launch timing conditional on the court’s judgment.

6) Settlement or covenant-not-to-sue agreements

• Many Paragraph IV cases end through settlement.
• Settlement terms shape:
  • entry date,
  • scope of authorized products,
  • licensing and royalty exposure.

---

Did Shionogi v. Nostrum end in a final judgment, settlement, or dismissal?

The request provides only the caption and docket number. Without docket disposition text (judgment, order, consent decree, or settlement filing), this response cannot state the outcome category.

Why outcome category matters commercially:

• Final infringement/validity ruling typically forces design-around or blocks launch until the patent expires.
• Settlement typically trades patent risk for fixed entry and may include “carve-outs” or license terms.
• Dismissal without merits raises uncertainty and can reframe risk depending on whether dismissal is procedural (no adjudication) or substantive (e.g., claim untethered to Orange Book listing).

---

When does Nostrum face exclusivity risk: patent expiry, market exclusivity, or both?

In Hatch-Waxman disputes, exclusivity risk typically blends:

1. Patent exclusivity via Orange Book patents
   • Entry is blocked until the court resolves infringement/invalidity for the asserted patents, or until those patents expire.
2. Regulatory exclusivity
   • 5-year NCE, 7-year orphan drug, 3-year new clinical investigation, and other exclusivity types can independently delay approval or marketing even after patent expiry depending on the NDA and exclusivity basis.
3. Statutory 30-month stay
   • The filing of a Paragraph IV notice triggers a 30-month stay (subject to exceptions), which often governs near-term entry more than later patent events.

But: this requires identifying the exact Shionogi brand, the ANDA reference, and the asserted patents. Those identifiers are not present in the request content.

---

What is the Orange Book status of the Shionogi product at issue?

Orange Book status requires:

• product name/active ingredient,
• NDA number,
• and the specific Orange Book listings tied to the asserted patents in the case.

No such product identifiers are included in the prompt, so this response cannot provide Orange Book listings.

---

How strong is Shionogi’s patent estate in this litigation compared with generic entry risk?

Patent estate strength in a single case is a function of:

• breadth of independent claims,
• whether the asserted patents include method-of-use or formulation barriers,
• likelihood of surviving invalidity contentions,
• and whether constructions favor the branded patent.

Those factors depend on:

• the asserted patent set,
• claim charts,
• and the court’s claim construction order or final opinion.

These are not included in the request content; therefore, no comparative strength analysis can be generated under the constraint.

---

What generic entry risks existed for Nostrum if it lost Shionogi’s patents?

If the defendant loses on infringement and validity:

• it faces an injunction barring commercial manufacture, use, sale, or offer for sale of the infringing ANDA product as determined by the court.
• the practical outcome is delayed entry until:
  • patent expiration,
  • an appeal decision,
  • or a settlement that permits later launch.

If the defendant wins:

• it can proceed to launch if FDA approval is in place and no other listed patents remain enforceable against the ANDA product.

Again, the request does not provide:

• the asserted patents,
• the court’s merits findings,
• or the case disposition.

---

Which companies besides Shionogi and Nostrum were involved and how does that affect licensing?

No party list beyond “Shionogi Inc. v. Nostrum Laboratories, Inc.” is provided. This response cannot identify co-defendants, licensors, or assignee entities without docket detail.

---

What patent litigation outcomes in D.N.J. Hatch-Waxman cases typically affect appeal and settlement leverage?

For investment and licensing analysis, the following general levers are relevant to this litigation type:

• Markman outcome: often drives settlement because it narrows the factual infringement/invalidity space.
• Summary judgment: can end or greatly reshape the asserted landscape.
• Final judgment with permanent injunction: increases settlement cost for the generic and increases settlement speed for the branded company.
• Appeal likelihood: a win on noninfringement can still lead to settlement if appellate risk remains.

No case-specific decisions are supplied, so these points remain generic.

---

Key Takeaways

• Docket identification: SHIONOGI INC. v. NOSTRUM LABORATORIES, INC., 1:12-cv-04402, is a D.N.J. Hatch-Waxman-style patent dispute filed in 2012.
• Business determinant: whether the court resolved the asserted Orange Book patents against Nostrum or whether the dispute ended through settlement or dismissal governs generic entry timing and licensing value.
• Missing litigation substance: the request does not provide the asserted patent numbers, court orders, opinions, or case disposition text, so a complete patent-specific and outcome-specific analysis cannot be stated in this response.

---

FAQs

What happens to an ANDA if a Paragraph IV lawsuit stays past 30 months?

ANS: Typically, the case outcome and any remaining statutory or patent barriers govern launch. (Patent-specific details depend on the disposition and Orange Book listings.)

Do settlement agreements in Hatch-Waxman always include entry dates?

ANS: Many do, through stipulated launch timing and/or license or covenant terms, but the exact structure depends on the settlement paperwork filed.

Can a generic launch “at risk” during an appeal?

ANS: It can, depending on the injunction posture, appellate stay, and whether the court’s order permits launch pending appeal.

How do method-of-use patents change design-around strategy?

ANS: Method-of-use claims can restrict even noninfringing formulations if the ANDA label or intended use practice matches the claimed steps.

What court decisions usually drive the biggest settlement moves?

ANS: Claim construction and dispositive rulings on infringement or invalidity.

---

References

No sources were cited because the request did not include docket opinion text, patent identifiers, or disposition documents required to support specific factual statements.